Analyst Reco. 89bio, Inc.

Equities

ETNB

US2825591033

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
8.26 ^USD	+0.12%		-9.03%	-26.05%

04-17	89bio, Inc. Appoints Martin Babler to Its Board of Directors	CI
04-03	89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	04-03	MT
Evercore ISI Adjusts 89bio Price Target to $37 From $29, Maintains Outperform Rating	03-07	MT
HC Wainwright Cuts Price Target on 89bio to $31 From $32, Keeps Buy Rating	03-01	MT
RBC Trims Price Target on 89bio to $14 From $15, Keeps Sector Perform, Speculative Risk	03-01	MT
RBC Downgrades 89bio to Sector Perform From Outperform, Cuts Price Target to $15 From $24 on View for 'Quieter Year,' Keeps Speculative Risk	01-12	MT
HC Wainwright Cuts 89bio Price Target to $32 From $35, Maintains Buy Rating	12-20	MT
RBC Cuts Price Target on 89bio to $24 From $27, Keeps Outperform, Speculative Risk	11-09	MT
UBS Cuts 89bio Price Target to $25 From $36, Maintains Buy Rating	23-10-12	MT
RBC Cuts Price Target on 89bio to $27 From $34 Amid 'Negative Read-Through' From 'Disappointing' Akero Data; Outperform, Speculative Risk Kept	23-10-11	MT
UBS Initiates Coverage on 89bio With Buy Rating, $36 Price Target	23-08-28	MT
Oppenheimer Cuts 89bio's Price Target to $30 From $33, Maintains Outperform Rating	23-08-16	MT
Cantor Fitzgerald Cuts Price Target on 89bio to $39 From $41, Maintains Overweight Rating	23-08-10	MT
RBC Lifts Price Target on 89bio to $34 From $33, Keeps Rating at Outperform, Speculative Risk	23-08-10	MT
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	23-07-07	DJ
BTIG Adjusts Price Target on 89bio to $37 From $30, Maintains Buy Rating	23-07-03	MT
Evercore ISI Initiates 89bio at Outperform With $49 Price Target	23-06-13	MT
HC Wainwright Adjusts 89bio's Price Target to $35 From $30, Keeps Buy Rating	23-05-08	MT
RBC Cuts Price Target on 89bio to $33 From $36, Maintains Outperform Rating, Speculative Risk Qualifier	23-05-05	MT
HC Wainwright Adjusts Price Target on 89bio to $30 From $25, Keeps Buy Rating	23-03-23	MT
RBC Capital Adjusts 89bio Price Target to $36 From $27, Maintains Outperform Rating	23-03-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. 89bio, Inc.

Equities

ETNB

US2825591033

Analyst Reco.

Filters